Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can MRI and computer models predict how well cancer drugs reach tumors?

NCT ID NCT04512209

NEW Knowledge-focused Sponsor: University Hospital, Ghent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers at Ghent University Hospital are studying whether MRI scans combined with computer models can measure the pressure inside tumors. High pressure in tumor tissue can block cancer drugs from reaching their target. The study enrolls 22 patients with pancreatic cancer or with ovarian or colon cancer that has spread to the abdomen. Participants have MRI scans before surgery, and during surgery researchers take tissue samples to measure stiffness and fluid flow. The goal is to see if the imaging and computer predictions match what is found in the tissue, which could help personalize cancer treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the approach works, doctors could one day use MRI and computer models to predict how well cancer drugs reach a tumor and tailor treatment for each patient.
What could go wrong
This is a small study of 22 people, and it only observes tissue properties rather than testing a new treatment. The computer models may not match real tumors well enough to guide care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

22 people

The number who actually took part.

Started

Oct 2019

Finished

Jul 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with non-cystic adenocarcinoma the pancreas requiring neoadjuvant chemotherapy (any) because of borderline resectability * Patients with stage IIIC or IVA ovarian cancer planned for debulking and HIPEC. * Patients with stage IIIC or IVA colorectal cancer planned for debulking and HIPEC Exclusion Criteria: * Age \<18 years * Pregnancy, or suspected inadequate contraception during study period * Clinically detectable ascites * Intestinal or urinary tract obstruction * Hepatic and/or extra-abdominal metastatic disease * Impaired renal function (serum creatinine \> 1.5mg/dl or calculated GFR (CKD-EPI) \< 60mL/min/1.73 m²) * Impaired liver function (serum total bilirubin \> 1.5 mg/dl, except for known Gilbert's disease) * Platelet count \< 100.000/µl * Hemoglobin \< 9g/dl * Neutrophil granulocytes \< 1.500/ml * Irresectable or metastatic disease * Contra-indication for contrast enhanced MRI * Known allergy or intolerance to Gadolinium based contrast agents * Severe claustrophobia * Patients with metallic foreign bodies (pacemaker, neurostimulator, pedicle screw, cerebral aneurysm clips…) that may dislodge in a strong magnetic field * Frail and medically unfit patients (Karnofsky index \< 60% and WHO Performance score 3 or 4) * Estimated life expectancy \< 12 months * In case of ovarian/colon cancer: no visible peritoneal metastasis on CT scan * Acute or chronic pancreatitis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinomatosis, peritoneal are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal cancer malignant pancreatic neoplasm ovarian cancer pancreatic adenocarcinoma pancreatic neoplasm peritoneal carcinomatosis peritoneal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinomatosis, peritoneal Colon cancer Ovarian cancer Pancreas cancer

Contacts and locations

Locations

  • Ghent University Hospital

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.